Evidence map›Paper›PMID 34391416›Full record

ArticleInternational journal for equity in health2021

Determinants of access to the SARS-CoV-2 vaccine: a preliminary approach.

Brigitte Renata Bezerra de Oliveira, Ana Iza Gomes da Penha Sobral, Marcelo Luiz Monteiro Marinho, Marcos Felipe Falcão Sobral, André de Souza Melo, Gisleia Benini Duarte

Abstract read
In one paragraph

Article in International journal for equity in health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Inequality in the distribution of Covid-19 vaccine: a systematic review.International journal for equity in health · 2022
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Observational
  9. Risk factors for death and illness severity in vaccinated versus unvaccinated COVID-2019 inpatients: a retrospective cohort study.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2023
    Observational
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines.Frontiers in cellular and infection microbiology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Brigitte Renata Bezerra de OliveiraDepartamento de Administração, Federal Rural University of Pernambuco, Avenida Dom Manoel de Medeiros, s/n - Dois Irmãos, Recife, PE, Brazil. renataoliveira@ufrpe.br.ORCID 0000-0003-0038-1053
Ana Iza Gomes da Penha SobralDepartamento de Psicologia Cognitiva, Federal University of Pernambuco, Av. Prof. Moraes Rego, 1235-Cidade Universitária, Recife, PE, 50670-901, Brazil.
Marcelo Luiz Monteiro MarinhoDepartamento de Computação, Federal Rural University of Pernambuco, Avenida Dom Manoel de Medeiros, s/n - Dois Irmãos, Recife, PE, Brazil.
Marcos Felipe Falcão SobralDepartamento de Administração, Federal Rural University of Pernambuco, Avenida Dom Manoel de Medeiros, s/n - Dois Irmãos, Recife, PE, Brazil.
André de Souza MeloDepartamento de Economia, Federal Rural University of Pernambuco, Avenida Dom Manoel de Medeiros, s/n - Dois Irmãos, Recife, PE, Brazil.
Gisleia Benini DuarteDepartamento de Economia, Federal Rural University of Pernambuco, Avenida Dom Manoel de Medeiros, s/n - Dois Irmãos, Recife, PE, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe determinants of access to immunizers are still poorly understood, leading to questions about which criteria were considered in this distribution. Given the above, the present study aimed to analyze the determinants of access to the SARS-CoV-2 vaccine by different countries.

methodsThe study covered 189 countries using data from different public databases, and collected until February 19, 2021. We used eight explanatory variables: gross domestic product (GDP), extreme poverty, human development index (HDI), life expectancy, median age, coronavirus disease 2019 (COVID-19) cases, COVID-19 tests, and COVID-19 deaths. The endogenous variables were total vaccine doses, vaccine doses per thousand, and days of vaccination. The structural equation modeling (SEM) technique was applied to establish the causal relationship between the country's COVID-19 impact, socioeconomic variables, and vaccine access. To support SEM, we used confirmatory factor analysis, t-test, and Pearson's correlation.

resultsWe collected the sample on February 19, and to date, 80 countries (42.1%) had already received a batch of immunizers against COVID-19. The countries with first access to the vaccine (e.g., number of days elapsed since they took the first dose) were the United Kingdom (68), China (68), Russia (66), and Israel (62). The countries receiving the highest doses were the United States, China, India, and Israel. The countries with extreme poverty had lower access to vaccines and the richer countries gained priority access. Countries most affected by COVID (deaths and cases) also received immunizers earlier and in greater volumes. Unfortunately, similar to other vaccines, indicators, such as income, poverty, and human development, influence vaccines' access. Thus affecting the population of vulnerable and less protected countries. Therefore, global initiatives for the equitable distribution of COVID need to be discussed and encouraged.

conclusionsDeterminants of vaccine distribution consider the impact of the disease in the country and are also affected by favorable socioeconomic indicators. The COVID-19 vaccines need to be accessible to all affected countries, regardless of their social hands.

Indexed as

COVID-19 VaccinesGlobal HealthHealth Care RationingHealth Services AccessibilityCOVID-19HumansSocioeconomic FactorsCOVID-19 VaccinesCOVID-19SARS-CoV-2 VaccinationVaccine distribution

Identifiers

PMID34391416
PMCPMC8363862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.